Michael Miller is a Neurology physician. ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Atwell Rd
Cooperstown, NY 133261301
Telephone
607-547-3240Registry record last updated 22 Feb 2008.
Clinical trials
- Creatine Timing on Resistance Training Adaptations in College Athletes
Sponsor: Rocky Mountain University of Health Professions
- Health, Aging and Later-Life Outcomes
Sponsor: Wake Forest University Health Sciences
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GE HealthCareProgram year20231 payment
- GENZYME CORPORATIONProgram year20211 payment
- SANOFI-AVENTIS U.S. LLCProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
89.4%Other antiepileptics20.5%Levetiracetam56%Topiramate31%Lacosamide12%Levetiracetam Er2%Part D<11 patientsGabapentinoids10.4%Gabapentin70%Pregabalin30%Part D≥44 patients+ 24 more classes in this area
Cardiovascular
3.7%Beta blocker3%Propranolol Hcl Er100%Part D≥17 patientsStatin0.7%Atorvastatin Calcium100%Part D<11 patientsMusculoskeletal
3%Central alpha-2 Adrenergic Agonist1.5%Tizanidine Hcl100%Part D≥11 patientsgamma-Aminobutyric Acid-ergic Agonist1.1%Baclofen100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
8 NIH research awards on record, funded 1991–2018 per NIH RePORTER. The latest:
- Identifying distinct striatonigral and striatopallidal disturbances
Icahn School of Medicine at Mount Sinai
FY2018$32,481F30DA038954 - Identifying distinct striatonigral and striatopallidal disturbances
Icahn School of Medicine at Mount Sinai
FY2017$49,044F30DA038954 - Identifying distinct striatonigral and striatopallidal disturbances
Icahn School of Medicine at Mount Sinai
FY2016$38,021F30DA038954
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”